Interactions of IgG1 CH2 and CH3 domains with FcRn

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Ying, Tianlei ^a   Ju, Tina W ^a   Wang, Yanping ^a,b   Prabakaran, Ponraj ^a,b   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Antibody fragments; CH2 domain; CH3 domain; FcRn; Small size

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; LIGHT SCATTERING; MOLECULAR DOCKING; NONHUMAN; NORMAL HUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PURIFICATION; SEQUENCE HOMOLOGY; SPECTROPHOTOMETRY; WESTERN BLOTTING;

EID: 84900849421     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00146     Document Type: Article

References (24)

1. Dimitrov DS. Therapeutic proteins. Methods Mol Biol (2012) 899:1-26. doi:10.1007/978-1-61779-921-1_1.
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol (2006) 6(5):343-57. doi:10.1038/nri1837.
3. Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol (2008) 8(5):600-8. doi:10.1016/j.coph.2008.07.006.
4. Chen W, Gong R, Ying T, Prabakaran P, Zhu Z, Feng Y, et al. Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains. Curr Drug Discov Technol (2014) 11(1):28-40.
5. Strohl WR, Strohl LM. Antibody fragments as therapeutics. Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry. Cambridge: Woodhead Publishing Series in Biomedicine (2013) p. 265-99.
6. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7(9):715-25. doi:10.1038/nri2155.
7. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol (2000) 18:739-66. doi:10.1146/annurev.immunol.18.1.739.
8. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs (2011) 3(5):422-30. doi:10.4161/mabs.3.5.16983.
9. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 337(3):141-7. doi:10.1056/NEJM199707173370301.
10. Gehlsen K, Gong R, Bramhill D, Wiersma D, Kirkpatrick S, Wang Y, et al. Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs (2012) 4(4):466-74. doi:10.4161/mabs.20652.
11. Ying T, Chen W, Feng Y, Wang Y, Gong R, Dimitrov DS. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem (2013) 288(35):25154-64. doi:10.1074/jbc.M113.484154.
12. Ying T, Chen W, Gong R, Feng Y, Dimitrov DS. Soluble monomeric IgG1 Fc. J Biol Chem (2012) 287(23):19399-408. doi:10.1074/jbc.M112.368647.
13. Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor. J Biol Chem (2011) 286(31):27288-93. doi:10.1074/jbc.M111.254219.
14. Gong R, Wang Y, Ying T, Dimitrov DS. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn. PLoS One (2012) 7(8):e42288. doi:10.1371/journal.pone.0042288.
15. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschlager M, Antes B, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel (2010) 23(4):289-97. doi:10.1093/protein/gzq005.
16. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, et al. Engineered human antibody constant domains with increased stability. J Biol Chem (2009) 284(21):14203-10. doi:10.1074/jbc.M900769200.
17. Gong R, Chen W, Dimitrov DS. Expression, purification, and characterization of engineered antibody CH2 and VH domains. Methods Mol Biol (2012) 899:85-102. doi:10.1007/978-1-61779-921-1_6.
18. Feng Y, Gong R, Dimitrov DS. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor. Protein Expr Purif (2011) 79(1):66-71. doi:10.1016/j.pep.2011.03.012.
19. Martin WL, West AP Jr, Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell (2001) 7(4):867-77. doi:10.1016/S1097-2765(01)00230-1.
20. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, Schwede T. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc (2009) 4(1):1-13. doi:10.1038/nprot.2008.197.
21. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem (2005) 26(16):1781-802. doi:10.1002/jcc.20289.
22. Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins (2003) 52(1):80-7. doi:10.1002/prot.10389.
23. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph (1996) 14(1):33-8. doi:10.1016/0263-7855(96)00018-5.
24. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol (2007) 372(3):774-97. doi:10.1016/j.jmb.2007.05.022.